Trial Search Results
Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata
The overall objectives of the study are to evaluate long-term safety of CTP-543 and to assess long-term effects of CTP-543 on treating hair loss in adult patients with chronic, moderate to severe alopecia areata.
Stanford is currently accepting patients for this trial.
- Drug: CTP-543
- Have completed 24 weeks of treatment in a previous qualifying CTP-543 clinical trial
- Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical
treatment to the scalp, significant trauma to the scalp, or untreated actinic
- Females who are nursing, pregnant, or planning to become pregnant while in the study,
and for 30 days after last dose of study medication
- Donation of blood at any point throughout the study and for 30 days after last dose of
Ages Eligible for Study
18 Years - 65 Years
Genders Eligible for Study